More Alzheimer’s drugs head for FDA review: what scientists are watching

More Alzheimer’s drugs head for FDA review: what scientists are watching

Nature, Published online: 15 November 2021; doi:10.1038/d41586-021-03410-9

Eli Lilly and other pharma firms have begun submitting their anti-amyloid drug hopefuls for approval. But questions linger over the controversial precedent set by Biogen’s aducanumab.
Source: Nature